These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29117251)

  • 41. Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
    Di Maro S; Di Leva FS; Trotta AM; Brancaccio D; Portella L; Aurilio M; Tomassi S; Messere A; Sementa D; Lastoria S; Carotenuto A; Novellino E; Scala S; Marinelli L
    J Med Chem; 2017 Dec; 60(23):9641-9652. PubMed ID: 29125295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Critical involvement of atypical chemokine receptor CXCR7 in allergic airway inflammation.
    Chang HC; Huang PH; Syu FS; Hsieh CH; Chang SL; Lu J; Chen HC
    Immunology; 2018 Jun; 154(2):274-284. PubMed ID: 29250768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NAD
    Lv H; Lv G; Chen C; Zong Q; Jiang G; Ye D; Cui X; He Y; Xiang W; Han Q; Tang L; Yang W; Wang H
    Cell Metab; 2021 Jan; 33(1):110-127.e5. PubMed ID: 33171124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.
    Shi Y; Riese DJ; Shen J
    Front Pharmacol; 2020; 11():574667. PubMed ID: 33363463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension.
    Hiraide T; Tsuda N; Momoi M; Shinya Y; Sano M; Fukuda K; Shibahara J; Kuramoto J; Kanai Y; Kosaki K; Hakamata Y; Kataoka M
    Sci Rep; 2024 Nov; 14(1):26604. PubMed ID: 39496725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New insight into ischemic stroke: Circadian rhythm in post-stroke angiogenesis.
    Zhang Y; Liu L; Zhao X; Yan S; Zeng F; Zhou D
    Front Pharmacol; 2022; 13():927506. PubMed ID: 36016550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
    Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
    Front Immunol; 2022; 13():942131. PubMed ID: 35958564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression.
    Murdamoothoo D; Sun Z; Yilmaz A; Riegel G; Abou-Faycal C; Deligne C; Velazquez-Quesada I; Erne W; Nascimento M; Mörgelin M; Cremel G; Paul N; Carapito R; Veber R; Dumortier H; Yuan J; Midwood KS; Loustau T; Orend G
    EMBO Mol Med; 2021 Jun; 13(6):e13270. PubMed ID: 33988305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.
    García-Cuesta EM; Santiago CA; Vallejo-Díaz J; Juarranz Y; Rodríguez-Frade JM; Mellado M
    Front Endocrinol (Lausanne); 2019; 10():585. PubMed ID: 31507535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4.
    Spinosa PC; Humphries BA; Lewin Mejia D; Buschhaus JM; Linderman JJ; Luker GD; Luker KE
    Sci Signal; 2019 Jul; 12(589):. PubMed ID: 31289212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer?
    Righetti A; Giulietti M; Šabanović B; Occhipinti G; Principato G; Piva F
    J Oncol; 2019; 2019():9681698. PubMed ID: 31275385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
    Scala S
    Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CXCL12/CXCR7 signaling axis, isoforms, circadian rhythms, and tumor cellular composition dictate gradients in tissue.
    Spinosa PC; Luker KE; Luker GD; Linderman JJ
    PLoS One; 2017; 12(11):e0187357. PubMed ID: 29117251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell, isoform, and environment factors shape gradients and modulate chemotaxis.
    Chang SL; Cavnar SP; Takayama S; Luker GD; Linderman JJ
    PLoS One; 2015; 10(4):e0123450. PubMed ID: 25909600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microfluidic platform for chemotaxis in gradients formed by CXCL12 source-sink cells.
    Torisawa YS; Mosadegh B; Bersano-Begey T; Steele JM; Luker KE; Luker GD; Takayama S
    Integr Biol (Camb); 2010 Nov; 2(11-12):680-6. PubMed ID: 20871938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential effects of CXCR4-CXCL12- and CXCR7-CXCL12-mediated immune reactions on murine P0106-125 -induced experimental autoimmune neuritis.
    Brunn A; Utermöhlen O; Mihelcic M; Sánchez-Ruiz M; Carstov M; Blau T; Ustinova I; Penfold M; Montesinos-Rongen M; Deckert M
    Neuropathol Appl Neurobiol; 2013 Dec; 39(7):772-87. PubMed ID: 23452257
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.